The North America Rare Diseases Treatment Market would witness market growth of 11.9% CAGR during the forecast period (2022-2028).
The presence of caring regulations by governmental agencies, like the Orphan Drug Act, which encourages product development by granting orphan drug designation to potential drug delivery developed by pharma companies, is expected to accelerate market growth. This initiative promotes research & development in the treatment of rare diseases.
Certain factors responsible for the growth of the rare disease treatment market include increased government assistance, incentives for pharmaceutical companies, raising consciousness among individuals and social groups, physician-to-physician communication to find effective treatment options for rare diseases, a rise in infrastructure for persons suffering from rare diseases, and an increment in research incentives due to the prevalence of non-proliferative diseases.
The increasing prevalence of rare diseases has encouraged key players to develop new and improved treatments, which are expected to propel the market over the future years. In addition, the government is making favourable rules and regulations for increasing the availability of rare disease treatments. Also, people's growing preference for a healthy lifestyle is demanding for the advanced healthcare facilities.
The presence of a large number of leading players, as well as advanced healthcare facilities, are some of the major factors expected to drive market growth in the near future. Besides that, rising reimbursement policies in order to organize treatments for patients who have rare diseases, would create more demand for advanced healthcare solutions. The healthcare initiatives of the United States government seek to contribute to broader U.S. development objectives, foreign policy priorities, as well as national security concerns, while also assisting in the improvement of people's health in low- and middle-income countries.
The US market dominated the North America Rare Diseases Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $65,458.2 million by 2028. The Canada market is experiencing a CAGR of 14.5% during (2022 - 2028). Additionally, The Mexico market is exhibiting a CAGR of 13.5% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable, Oral, and Others. Based on Therapeutic Area, the market is segmented into Cancer, Cardiovascular Conditions, Infectious Diseases, Musculoskeletal Conditions, Endocrine Disorders, Metabolic Disorders, Hematologic Disorders, Neurological Conditions, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Rare Diseases Treatment Market is Estimated to reach $255.4 Billion by 2028, at a CAGR of 12.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Merck Group, Bristol Myers Squibb Company, Pfizer, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited and PTC Therapeutics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Biologics
- Biosimilar
- Small Molecule
By Distribution Channel
- Specialty Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By Route of Administration
By Therapeutic Area
- Cancer
- Cardiovascular Conditions
- Infectious Diseases
- Musculoskeletal Conditions
- Endocrine Disorders
- Metabolic Disorders
- Hematologic Disorders
- Neurological Conditions
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Novartis AG
- Merck Group
- Bristol Myers Squibb Company
- Pfizer, Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- PTC Therapeutics, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Rare Diseases Treatment Market, by Drug Type
1.4.2 North America Rare Diseases Treatment Market, by Distribution Channel
1.4.3 North America Rare Diseases Treatment Market, by Route of Administration
1.4.4 North America Rare Diseases Treatment Market, by Therapeutic Area
1.4.5 North America Rare Diseases Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2018, Jul – 2022, Aug) Leading Players
Chapter 4. North America Rare Diseases Treatment Market by Drug Type
4.1 North America Biologics Market by Country
4.2 North America Biosimilar Market by Country
4.3 North America Small Molecule Market by Country
Chapter 5. North America Rare Diseases Treatment Market by Distribution Channel
5.1 North America Specialty Pharmacy Market by Country
5.2 North America Hospital Pharmacy Market by Country
5.3 North America Online Pharmacy Market by Country
Chapter 6. North America Rare Diseases Treatment Market by Route of Administration
6.1 North America Injectable Market by Country
6.2 North America Oral Market by Country
6.3 North America Others Market by Country
Chapter 7. North America Rare Diseases Treatment Market by Therapeutic Area
7.1 North America Cancer Market by Country
7.2 North America Cardiovascular Conditions Market by Country
7.3 North America Infectious Diseases Market by Country
7.4 North America Musculoskeletal Conditions Market by Country
7.5 North America Endocrine Disorders Market by Country
7.6 North America Metabolic Disorders Market by Country
7.7 North America Hematologic Disorders Market by Country
7.8 North America Neurological Conditions Market by Country
7.9 North America Others Market by Country
Chapter 8. North America Rare Diseases Treatment Market by Country
8.1 US Rare Diseases Treatment Market
8.1.1 US Rare Diseases Treatment Market by Drug Type
8.1.2 US Rare Diseases Treatment Market by Distribution Channel
8.1.3 US Rare Diseases Treatment Market by Route of Administration
8.1.4 US Rare Diseases Treatment Market by Therapeutic Area
8.2 Canada Rare Diseases Treatment Market
8.2.1 Canada Rare Diseases Treatment Market by Drug Type
8.2.2 Canada Rare Diseases Treatment Market by Distribution Channel
8.2.3 Canada Rare Diseases Treatment Market by Route of Administration
8.2.4 Canada Rare Diseases Treatment Market by Therapeutic Area
8.3 Mexico Rare Diseases Treatment Market
8.3.1 Mexico Rare Diseases Treatment Market by Drug Type
8.3.2 Mexico Rare Diseases Treatment Market by Distribution Channel
8.3.3 Mexico Rare Diseases Treatment Market by Route of Administration
8.3.4 Mexico Rare Diseases Treatment Market by Therapeutic Area
8.4 Rest of North America Rare Diseases Treatment Market
8.4.1 Rest of North America Rare Diseases Treatment Market by Drug Type
8.4.2 Rest of North America Rare Diseases Treatment Market by Distribution Channel
8.4.3 Rest of North America Rare Diseases Treatment Market by Route of Administration
8.4.4 Rest of North America Rare Diseases Treatment Market by Therapeutic Area
Chapter 9. Company Profiles
9.1 AbbVie, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.2 F. Hoffmann-La Roche Ltd.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Acquisition and Mergers:
9.3 Bayer AG
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 Novartis AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Approval and Trails:
9.5 Merck Group
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.6 Bristol Myers Squibb Company
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 Recent strategies and developments:
9.6.5.1 Acquisition and Mergers:
9.7 Pfizer, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional & Segmental Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Acquisitions and Mergers:
9.8 AstraZeneca PLC
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Acquisition and Mergers:
9.9 Takeda Pharmaceutical Company Limited
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.9.5.2 Acquisition and Mergers:
9.10. PTC Therapeutics, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
9.10.5.2 Acquisition and Mergers:
TABLE 1 North America Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 2 North America Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements – Rare Disease Treatment Market
TABLE 4 Acquisition and Mergers – Rare Disease Treatment Market
TABLE 5 Approvals and Trials – Rare Disease Treatment Market
TABLE 6 North America Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 7 North America Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 8 North America Biologics Market by Country, 2018 - 2021, USD Million
TABLE 9 North America Biologics Market by Country, 2022 - 2028, USD Million
TABLE 10 North America Biosimilar Market by Country, 2018 - 2021, USD Million
TABLE 11 North America Biosimilar Market by Country, 2022 - 2028, USD Million
TABLE 12 North America Small Molecule Market by Country, 2018 - 2021, USD Million
TABLE 13 North America Small Molecule Market by Country, 2022 - 2028, USD Million
TABLE 14 North America Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 15 North America Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 16 North America Specialty Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 17 North America Specialty Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 18 North America Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 19 North America Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 20 North America Online Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 21 North America Online Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 22 North America Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 23 North America Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 24 North America Injectable Market by Country, 2018 - 2021, USD Million
TABLE 25 North America Injectable Market by Country, 2022 - 2028, USD Million
TABLE 26 North America Oral Market by Country, 2018 - 2021, USD Million
TABLE 27 North America Oral Market by Country, 2022 - 2028, USD Million
TABLE 28 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 29 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 30 North America Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 31 North America Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 32 North America Cancer Market by Country, 2018 - 2021, USD Million
TABLE 33 North America Cancer Market by Country, 2022 - 2028, USD Million
TABLE 34 North America Cardiovascular Conditions Market by Country, 2018 - 2021, USD Million
TABLE 35 North America Cardiovascular Conditions Market by Country, 2022 - 2028, USD Million
TABLE 36 North America Infectious Diseases Market by Country, 2018 - 2021, USD Million
TABLE 37 North America Infectious Diseases Market by Country, 2022 - 2028, USD Million
TABLE 38 North America Musculoskeletal Conditions Market by Country, 2018 - 2021, USD Million
TABLE 39 North America Musculoskeletal Conditions Market by Country, 2022 - 2028, USD Million
TABLE 40 North America Endocrine Disorders Market by Country, 2018 - 2021, USD Million
TABLE 41 North America Endocrine Disorders Market by Country, 2022 - 2028, USD Million
TABLE 42 North America Metabolic Disorders Market by Country, 2018 - 2021, USD Million
TABLE 43 North America Metabolic Disorders Market by Country, 2022 - 2028, USD Million
TABLE 44 North America Hematologic Disorders Market by Country, 2018 - 2021, USD Million
TABLE 45 North America Hematologic Disorders Market by Country, 2022 - 2028, USD Million
TABLE 46 North America Neurological Conditions Market by Country, 2018 - 2021, USD Million
TABLE 47 North America Neurological Conditions Market by Country, 2022 - 2028, USD Million
TABLE 48 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 49 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 50 North America Rare Diseases Treatment Market by Country, 2018 - 2021, USD Million
TABLE 51 North America Rare Diseases Treatment Market by Country, 2022 - 2028, USD Million
TABLE 52 US Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 53 US Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 54 US Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 55 US Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 56 US Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 57 US Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 58 US Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 59 US Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 60 US Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 61 US Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 62 Canada Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 63 Canada Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 64 Canada Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 65 Canada Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 66 Canada Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 67 Canada Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 68 Canada Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 69 Canada Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 70 Canada Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 71 Canada Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 72 Mexico Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 73 Mexico Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 74 Mexico Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 75 Mexico Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 76 Mexico Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 77 Mexico Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 78 Mexico Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 79 Mexico Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 80 Mexico Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 81 Mexico Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 82 Rest of North America Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 83 Rest of North America Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 84 Rest of North America Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 85 Rest of North America Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 86 Rest of North America Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 87 Rest of North America Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 88 Rest of North America Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 89 Rest of North America Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 90 Rest of North America Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 91 Rest of North America Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 92 Key information – AbbVie, Inc.
TABLE 93 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 94 Key Information – Bayer AG
TABLE 95 Key Information – Novartis AG
TABLE 96 key Information – Merck GrouP
TABLE 97 Key Information – Bristol Myers Squibb Company
TABLE 98 Key Information – Pfizer, Inc.
TABLE 99 KEY INFORMATION – ASTRAZENECA PLC
TABLE 100 Key Information – Takeda Pharmaceutical Company Limited
TABLE 101 Key Information – PTC Therapeutics, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Acquisitions and Mergers: 2018, Jul – 2022, Aug) Leading Players
FIG 5 Recent strategies and developments: Pfizer, Inc.
FIG 6 Recent strategies and developments: PTC Therapeutics, Inc.